Drug Profile
Diazepam - Aquestive Therapeutics
Alternative Names: AQST-203; DBF; DBSF; Diazepam BSF; Diazepam buccal soluble film - Aquestive Therapeutics; LibervantLatest Information Update: 22 Apr 2024
Price :
$50
*
At a glance
- Originator MonoSol Rx
- Developer Aquestive Therapeutics
- Class Antiepileptic drugs; Anxiolytics; Benzodiazepines; Benzodiazepinones; Hypnosedatives; Muscle relaxants; Small molecules
- Mechanism of Action GABA A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Registered Seizures
- Phase III Epilepsy
Most Recent Events
- 22 Apr 2024 Aquestive Therapeutics plans for the commercial launch of diazepam for Seizures in USA in 2027 (Aquestive Therapeutics pipeline, April 2024)
- 11 Sep 2023 FDA assigns PDUFA action date of (28/04/2024) for diazepam for Seizures (In children)
- 11 Sep 2023 FDA assigns PDUFA action date of (28/04/2024) for diazepam for Seizures (In children)